

# Cryo Characterization Report (CCR)

Lot Overview		
Lot Number	Qualification	Catalog Number
HUM4122D	Cryopreserved human hepatocytes Plateable, Transporter Certified	HUCPQ


Donor Demographics								
Sex	Race	Age	BMI	Tobacco Use	Alcohol Use	Drug Use	HIV, HBV, HCV Serologies	Cause of Death
Male	Asian	35	31	1ppd	2 beers/day	Quit in 2014	Negative	Fall

Additional donor demographic information, including relevant medical and medication history, is available upon request

Post-thaw Viability and Cell Quality Assessment			
Thawing Medium Used	Centrifuge Conditions	% Viability (post-thaw)	Viable cell yield per vial
Cryopreserved Human Hepatocyte Thawing Medium	100 x g for 8 min	88%	5.3 x 10 <sup>6</sup> viable cells

Monolayer Assessment					
Plating Medium Used	Culture Medium Used	Time Change to Culture Medium	Optimal Seeding Density	Initial Attachment Efficiency	Monolayer Confluency after 96hrs in culture
Human Hepatocyte Plating Medium	Hepatocyte Maintenance Medium	6hrs	0.8 X 10 <sup>6</sup> cells/mL	95%	100%

Characterization was completed in a 24-well collagen-coated plate with extra-cellular matrix overlay



HUM4122D, 48hrs, 10X



HUM4122D, 72hrs, 10X

# Cryo Characterization Report (CCR)



<i>Induction</i>			
Isoforms	Control Inducer	Fold Induction Specific Activity	Fold Induction mRNA Expression
<i>CYP1A2</i>	<i>50µM Omeprazole</i>	<i>50.0</i>	<i>39.2</i>
<i>CYP2B6</i>	<i>1 mM Phenobarbital</i>	<i>40.9</i>	<i>29.7</i>
<i>CYP3A4</i>	<i>10µM Rifampicin</i>	<i>33.8</i>	<i>45.2</i>

Cryopreserved human hepatocytes were thawed and plated on 24-well collagen I coated plates, overlaid with Matrigel<sup>®</sup>, then dosed in triplicate with vehicle control (0.1% DMSO) or control inducers for 72 hours. The fold induction was calculated by dividing the induced level by the vehicle control level.

*Media products used for characterization:*

MCHT50 –Cryopreserved human hepatocyte thawing medium, 50mL

MP250 – Human hepatocyte plating medium, 250mL

MM250 – Hepatocyte maintenance medium, 250mL

Contact customer service to place an order or to obtain additional information on any of our cryopreserved primary hepatocyte lots.

**To contact TRL:**

Phone: 919-549-3593

Email: [customerservice@trlcells.com](mailto:customerservice@trlcells.com)

Web: [www.triangleresearchlabs.com](http://www.triangleresearchlabs.com)



## Transporter Certified™ Hepatocytes



**Vendor: Triangle Research Labs**

**Lot #: HUM4122D** Adult Male Asian

### Culture Characteristics

Characteristic	Average
Post-Thaw Viability	82.3%
Protein Content (µg/well in 24-well)	163

Cryopreserved hepatocytes were thawed following manufacturer's thawing instructions in QTS proprietary thaw medium. Hepatocytes were suspended in QTS proprietary hepatocyte seeding medium (QualGro™ Seeding Medium) at a density of 0.8 million viable cells/mL onto BioCoat® 24-well cell culture plates. Following plating, cells were allowed to attach for 2-4 hours, rinsed and fed with warm (37°C) seeding medium. Eighteen to 24 hours later, cells were fed and overlaid with QualGro™ Human Hepatocyte Culture Medium supplemented with extracellular matrix (ECM), Matrigel® (0.35 mg/mL). Sandwich culture hepatocytes were maintained in QualGro™ Hepatocyte Culture Medium for five days prior to assessment of transporter function.



Phase-contrast image of plated sandwich-cultured hepatocytes (Day 5) using QTS proprietary media, plating, overlay and culturing protocols is shown (left). Hepatocyte repolarization and bile pocket formation is shown utilizing CDFDA staining (right).

## Transporter Activity

Using clinically relevant probe substrates, transport activity of uptake (accumulation) and efflux (biliary excretion) transporters is quantitated and function is compared to our historical hepatocyte database.

Probe Substrate	Hepatic Transporter	% Transported Relative to QTS Historical Fresh Database
Rosuvastatin	Uptake (OATPs)	179
Pravastatin	Uptake (OATPs)	38.5
Taurocholate	Uptake (NTCP, OATPs)	73.6
Taurocholate	Efflux (BSEP)	77.3
Digoxin	Efflux (P-gp)	113
Rosuvastatin	Efflux (MRP2, BCRP)	92.0
Pravastatin	Efflux (BCRP, MRP2)	196

Percentages > 100% indicated higher transporter function compared to historical fresh human hepatocyte database. Percentages < 100% indicated lower transporter function compared to historical fresh human hepatocyte database.

The intracellular concentration is the driving force for all of the processes that take place inside the hepatocyte. The intracellular concentration of a drug is a function of its hepatic uptake, metabolism and efflux (both basolateral and canalicular). QTS Transporter Certified™ hepatocytes are evaluated for functional uptake (accumulation) and efflux (biliary excretion) transporters using clinically relevant probe substrates covering key hepatic transporters, and compared to fresh primary hepatocytes since activity in fresh primary hepatocytes is considered the “gold standard.”

## Hepatic Exposure (Kp Ratio)


The Kp ratio is the ratio of the intracellular concentration of a compound to its medium concentration following exposure for a given time. This indicates the extent of accumulation of a compound within the hepatocyte.

Transporter Substrate	HUM4122D Kp Ratio	QTS Historic Fresh Database Kp Ratio
Taurocholate	4.98	1.74 – 7.81
Digoxin	3.33	0.566 – 6.76
Rosuvastatin	6.12	1.55 – 6.05
Pravastatin	0.140	0.241 – 0.906

Compounds that are substrates for uptake transporters can accumulate significantly in the liver. The ratio of a compound’s intracellular concentration to its medium concentration (Kp ratio) has been shown to correlate with the liver : blood ratio in vivo. A high Kp ratio suggests intracellular accumulation, and may be predictive of hepatic accumulation in vivo.

## Conjugation Capacity and Biliary Excretion

Metabolism of naloxone by Phase II enzymes (glucuronidation) is determined, as well as the disposition of both parent and metabolite.



Measurement of metabolic capacity is key to evaluating the interaction between metabolism and transport. The metabolism of naloxone to its primary glucuronide metabolite is measured in cells and medium. The biliary excretion index (BEI) of naloxone glucuronide was determined to be 70.3%. After 40 minutes exposure, approximately 59.0% of the naloxone in the medium had been converted to the glucuronide metabolite. This demonstrates uptake transporter function (naloxone), phase II metabolism (conversion to naloxone-3-glucuronide), as well as both basolateral and biliary efflux transporter function (media and bile presence of naloxone-3-glucuronide, respectively).

## Bile Acid Profile

Human hepatocytes synthesize the primary bile acids cholic acid and chenodeoxycholic acid, and conjugate them to glycine and taurine, both in characterized ratios. These ratios are determined in QTS Transporter Certified hepatocytes that are cultured using proprietary culture conditions and medium, and ratios are compared to those reported in vivo.

Source	% Glycine Conjugates	% Taurine Conjugates
HUM4122D	75 %	25 %
QTS Historical Database	64 %	36 %
<i>In Vivo</i>	75 %	25 %

One of the major functions of the liver is to synthesize bile acids, which are secreted into the bile to aid in digestion and absorption of critical lipid-soluble nutrients. Under the correct conditions, hepatocytes can maintain this function and synthesize primary bile acids and their conjugates in vitro. Bile acids and their conjugates have different physicochemical properties and vary in their relative amounts in vivo. Therefore, in vivo-relevant baseline profiles of the primary bile acids

and their conjugates in vitro are critical when using hepatocytes to evaluate a compound's potential to alter the hepatobiliary disposition of bile acids, which may lead to hepatotoxicity. Using proprietary culture medium and technology, the ratio of glycine : taurine (G:T) conjugated bile acids, are determined and compared to established in vivo values.

## Drug-Transporter Interactions

Assessment of interactions between major hepatic transporters using specific, clinically-relevant probe substrates (taurocholate, digoxin, pravastatin, rosuvastatin) with and without a known broad-spectrum inhibitor (erythromycin estolate) demonstrates specific transporter activity as well as inhibition. Results are compared to activity without inhibitor.

Transporter Certified™ hepatocytes in sandwich culture are the optimal system for evaluating the transporter interaction potential of new chemical entities. Knowledge of the potential for the function of key transporters (uptake and efflux) to be altered is critical for the evaluation of drug interactions with either other drugs or endogenous compounds.

Effect of Inhibitor on Hepatic Transporter Function	HUM4122D (% Untreated)	QTS Historical Fresh Database (% Untreated)
Uptake (OATP)	9.4 %	8.8 – 34.7 %
Uptake (NTCP)	2.4 %	3.1 – 8.9 %
Canalicular Efflux (BSEP)	16.2 %	0.0 – 75.7 %
Canalicular Efflux (P-gp)	43.9 %	6.4 – 27.8 %
Canalicular Efflux (MRP2)	30.0 %	0.0 – 44.8 %
Canalicular Efflux (BCRP)	11.4 %	0.0 – 79.9 %

The % untreated reflects the change in transporter function in the presence of an inhibitor with respect to control incubations (without an inhibitor), as a measure of the degree to which transporter function has been inhibited. Ranges for percent function remaining following treatment with the same broad spectrum inhibitor in the QTS Historical Fresh Database are provided for comparison.